{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Endpoint', 'Statistical Analysis Methods', 'Secondary endpoint change from baseline in SGRQ total score at Week 4 (Day', '28) and Week 12 (Day 84) will be analysed for the ITT Population using MMRM', 'analysis, including covariates of baseline, geographical region, treatment and visit', 'by baseline interaction. A visit by treatment interaction term will also be included', 'to allow treatment effects to be estimated at each visit separately. The variance-', 'covariance matrix will be assumed unstructured. Estimated differences between', 'FF/UMEC/VI and tiotropium will be presented together with 95 \u00b0 % CI for the', 'difference and p-value.', 'Other', 'Will be described in the reporting and analysis plan.', '10.4.2.', 'Safety Analyses', 'All safety analyses will be performed on the ITT Population.', 'Endpoint', 'Statistical Analysis Methods', 'Primary', 'There is no primary safety analysis.', 'Secondary', 'The following safety endpoints will be analysed descriptively by treatment group:', 'Incidence of adverse events', 'Incidence of adverse events of special interest (AESI)', 'Vital signs', 'Details will be described in the reporting and analysis plan', 'Adverse events (AEs) will be coded using the standard GSK dictionary, Medical', 'Dictionary for Regulatory Activities (MedDRA), and grouped by body system. The', 'number and percentage of participants experiencing at least one AE of any type, AEs', 'within each body system and AEs within each preferred term will be presented for each', 'treatment group. Separate summaries will be provided for all AEs, drug related AEs, fatal', 'AEs, non-fatal SAEs, adverse events of special interest (AESIs) and AEs leading to', 'withdrawal. Deaths and SAEs, if applicable, will be documented in case narrative format.', '10.4.3.', 'Other Analyses', 'Full details of the analyses to be performed on the primary and other efficacy endpoints', 'will be given in the Reporting and Analysis Plan (RAP).', '10.4.4.', 'Interim Analyses', 'No interim analysis is planned for this study.', '73']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '10.4.5.', 'Exploratory Analyses', 'These exploratory analyses may be provided in a separate RAP.', '74']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '11.', 'REFERENCES', 'Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al.', 'Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for', 'Treatment of Chronic Obstructive Pulmonary Disease A Randomized Trial. Ann Intern', 'Med 2007; 146:545-555.', 'Cazzola M, And\u00f2 F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, et al. A pilot study to', 'assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the', 'airflow obstruction of patients with severe-to-very severe COPD. Pul Pharm Ther 2007;', '20:556-561.', 'Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of', 'patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004; 23:', '932-946.', 'Christensson C, Thoren A, Lindberg B. Safety of inhaled budesonide: clinical', 'manifestations of systemic corticosteroid-related adverse effects. Drug Safety.', '2008;31:965-988.', 'Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. Pneumonia', 'risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH', 'study results. EUR Respier /2009;34:641-647.', 'De Bisschop MB, Bellou A. Anaphylaxis. Curr Opin Crit Care. 2012;18:308-317.', \"Dransfield MT, Bailey W, Crater G, Emmett A, O'Dell DM, Yawn B. Disease severity\", 'and symptoms among subjects receiving monotherapy for COPD. Prim Care Resp J', '2011; 20): 46-53.', 'Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. Once-', 'daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of', 'exacerbations of COPD: two replicate double-blind, parallel-group, randomised', 'controlled trials. Lancet Respir Med 2013;1:210-223.', 'Global Strategy for the Diagnosis, Management and Prevention of COPD, Global', 'Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from:', 'heep://www.goldcopd.org/.', 'Global Strategy for the Diagnosis, Management and Prevention of COPD, Global', 'Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from:', 'http://www.goldcopd.org/.', 'GOLD. Global Initiative for Chronic Obstructive Lung Disease (Updated 2011).', 'http://www.copdgold.org.', \"Hanania HA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.\", '(Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe', 'COPD. Resp Med 2012; 106: 91-101.', '75']\n\n###\n\n", "completion": "END"}